Cellectar Biosciences Inc. (CLRB) announced Wednesday morning that preliminary results of its in vivo study showed that tumor uptake of CLR 1602's paclitaxel payload increased by more than 30-fold over free paclitaxel.
from RTT - Before the Bell http://ift.tt/1txXunX
via IFTTT
No comments:
Post a Comment